Story perspectives

New Gene Discovery Boosts Cancer Immunotherapy Effectiveness

3/10/2026

Summary

Story summary

Researchers from Monash University and oNKo-Innate in Melbourne identified a gene that, when switched off in natural killer cells, increases sensitivity to interleukin-15 (IL-15) and boosts anti-tumor activity.
In preclinical models, disabling this gene improved natural killer cell activity and slowed colorectal cancer growth.
The findings suggest targeting this gene could yield safer cancer therapies that boost tumor-immune responses while sparing healthy tissue.
The approach could also complement existing immunotherapies.

1 of 1

Story summary

Researchers from Monash University and oNKo-Innate in Melbourne identified a gene that, when switched off in natural killer cells, increases sensitivity to interleukin-15 (IL-15) and boosts anti-tumor activity.
In preclinical models, disabling this gene improved natural killer cell activity and slowed colorectal cancer growth.
The findings suggest targeting this gene could yield safer cancer therapies that boost tumor-immune responses while sparing healthy tissue.
The approach could also complement existing immunotherapies.